Topiramate injection - CyDex

Drug Profile

Topiramate injection - CyDex

Alternative Names: Captisol®-enabled topiramate IV; Captisol®-enabled topiramate injection

Latest Information Update: 06 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CyDex Pharmaceuticals
  • Developer CyDex Pharmaceuticals; University of Minnesota
  • Class Antiepileptic drugs; Antimigraines; Hexoses; Ketoses; Neuroprotectants; Obesity therapies; Small molecules; Sulfonic acids
  • Mechanism of Action AMPA receptor antagonists; Carbonic anhydrase inhibitors; GABA A receptor agonists; Kainic acid receptor antagonists; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Epilepsy; Seizures
  • New Molecular Entity No

Highest Development Phases

  • Phase I Epilepsy; Seizures

Most Recent Events

  • 06 Apr 2018 Topiramate injection is still in phase I trials for Seizures and Epilepsy in USA ((IM and IV Injection) (Ligand Pharmaceuticals pipeline, April 2018)
  • 28 Feb 2018 No recent reports of development identified for phase-I development in Epilepsy in USA (IM, Injection)
  • 28 Feb 2018 No recent reports of development identified for phase-I development in Epilepsy in USA (IV, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top